bioAffinity Technologies received written notice from Nasdaq confirming it has regained compliance with the Minimum Bid Price Rule and Rights/Warrants Rule, allowing its common stock and warrants to continue trading on the Nasdaq Capital Market. Consequently, a scheduled hearing before the Nasdaq Hearings Panel was cancelled. The company had previously been notified of non-compliance due to a bid price below $1.00 per share for thirty consecutive days but was ineligible for a standard compliance period because it executed a reverse stock split within the prior year. As of September 8, 2026, there were 1,166,625 outstanding shares with an aggregate market value of approximately $10.4 million. bioAffinity Technologies operates in the biotechnology industry, developing noninvasive healthcare solutions for the early detection and monitoring of lung disease.

bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for asthma and COPD. The partnership integrates bioAffinity's flow cytometry expertise with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles. bioAffinity Technologies, Inc. is a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics.

On July 7, 2026, bioAffinity Technologies, Inc. announced that commercial sales for its noninvasive lung cancer diagnostic, CyPath® Lung, have grown by more than 200% year-over-year. The company operates in the biotechnology industry and develops diagnostic tests for cancer.